Diagnostic Products teams up with Compugen
This article was originally published in Clinica
Compugen has agreed to give Diagnostic Products, a Los Angeles, California-based immunodiagnostic testing company, access to its portfolio of biomarkers, which the latter will use for developing and commercialising immunoassay and DNA-based diagnostic products. In return, Tel Aviv, Israel-based Compugen will receive development milestone payments and royalties on the sales of these products. In addition, the two companies are to collaborate on discovering new biomarker candidates for both therapeutic and diagnostic applications.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.